Immutep Limited (IMM.AX)
AUD 0.35
(-4.17%)
AUD 0.35
(-4.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -44.93 Million AUD | -32.41% |
| 2021 | -33.93 Million AUD | -73.5% |
| 2020 | -19.56 Million AUD | -22.11% |
| 2019 | -16.01 Million AUD | 21.54% |
| 2018 | -20.41 Million AUD | -74.6% |
| 2017 | -11.69 Million AUD | -25.03% |
| 2016 | -9.35 Million AUD | 84.79% |
| 2015 | -61.47 Million AUD | -341.5% |
| 2014 | -13.92 Million AUD | -4.46% |
| 2013 | -13.32 Million AUD | 11.75% |
| 2012 | -15.1 Million AUD | 18.14% |
| 2011 | -18.45 Million AUD | -30.59% |
| 2010 | -14.13 Million AUD | -79.08% |
| 2009 | -7.89 Million AUD | -235.06% |
| 2008 | -2.35 Million AUD | -25.49% |
| 2007 | -1.87 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 Q2 | -23.1 Million AUD | 0.0% |
| 2022 Q4 | -21.83 Million AUD | 0.0% |
| 2022 FY | -44.93 Million AUD | -32.41% |
| 2021 FY | -33.93 Million AUD | -73.5% |
| 2021 Q2 | -18.92 Million AUD | 0.0% |
| 2021 Q4 | -19.45 Million AUD | 0.0% |
| 2020 FY | -19.56 Million AUD | -22.11% |
| 2020 Q4 | -10.91 Million AUD | 0.0% |
| 2020 Q2 | -12.6 Million AUD | 0.0% |
| 2019 Q2 | -8.58 Million AUD | 0.0% |
| 2019 FY | -16.01 Million AUD | 21.54% |
| 2019 Q4 | -12.73 Million AUD | 0.0% |
| 2018 Q4 | -12.91 Million AUD | 0.0% |
| 2018 Q2 | -9.49 Million AUD | 0.0% |
| 2018 FY | -20.41 Million AUD | -74.6% |
| 2017 FY | -11.69 Million AUD | -25.03% |
| 2017 Q4 | -6.88 Million AUD | 0.0% |
| 2017 Q2 | -5.3 Million AUD | 0.0% |
| 2016 Q3 | -1.76 Million AUD | 57.08% |
| 2016 Q4 | -3.55 Million AUD | -101.94% |
| 2016 FY | -9.35 Million AUD | 84.79% |
| 2016 Q2 | -4.1 Million AUD | 0.0% |
| 2015 FY | -61.47 Million AUD | -341.5% |
| 2015 Q4 | -3.62 Million AUD | -39.56% |
| 2015 Q3 | -2.59 Million AUD | 95.32% |
| 2015 Q2 | -55.42 Million AUD | 0.0% |
| 2014 Q2 | -6.96 Million AUD | 0.0% |
| 2014 FY | -13.92 Million AUD | -4.46% |
| 2014 Q4 | -7.71 Million AUD | 0.0% |
| 2013 Q2 | -6.8 Million AUD | 0.0% |
| 2013 FY | -13.32 Million AUD | 11.75% |
| 2013 Q4 | -7.64 Million AUD | 0.0% |
| 2012 FY | -15.1 Million AUD | 18.14% |
| 2012 Q4 | -9.18 Million AUD | 0.0% |
| 2012 Q2 | -8.27 Million AUD | 0.0% |
| 2011 FY | -18.45 Million AUD | -30.59% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | -14.13 Million AUD | -79.08% |
| 2009 FY | -7.89 Million AUD | -235.06% |
| 2008 FY | -2.35 Million AUD | -25.49% |
| 2007 FY | -1.87 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 562.479% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -2979.72% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -656.741% |
| Biome Australia Limited | -1.91 Million AUD | -2248.74% |
| Patrys Limited | -3.53 Million AUD | -1169.713% |
| Orthocell Limited | -11.68 Million AUD | -284.698% |
| Imugene Limited | -140.93 Million AUD | 68.114% |
| Noxopharm Limited | -7.53 Million AUD | -496.377% |
| PYC Therapeutics Limited | -38.85 Million AUD | -15.647% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | -265.055% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -525.305% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -521.403% |
| Cynata Therapeutics Limited | -8.8 Million AUD | -410.189% |
| CSL Limited | 5.64 Billion AUD | 100.795% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -524.729% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -1367.349% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 191.432% |
| Starpharma Holdings Limited | -15.15 Million AUD | -196.438% |
| Nanollose Limited | -1.24 Million AUD | -3495.466% |
| Memphasys Limited | -2.7 Million AUD | -1561.872% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -2006.133% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -2085.058% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -915.533% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | -205.697% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -1463.69% |
| Race Oncology Limited | -13.38 Million AUD | -235.838% |
| Nyrada Inc. | -4.56 Million AUD | -885.39% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | -79.319% |
| PharmAust Limited | -6.65 Million AUD | -574.869% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | -0.304% |
| Alterity Therapeutics Limited | -19.6 Million AUD | -129.251% |
| BTC Health Limited | 1.05 Million AUD | 4358.276% |
| Acrux Limited | -9.83 Million AUD | -356.956% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 119.887% |
| Biotron Limited | -5.15 Million AUD | -772.366% |
| Tissue Repair Ltd | -4.87 Million AUD | -821.605% |
| AdAlta Limited | -5.26 Million AUD | -754.058% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 4.814% |
| Hexima Limited | -1 Million AUD | -4354.724% |
| AnteoTech Limited | -11.72 Million AUD | -283.206% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 30.985% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | -103.785% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -879.193% |
| Actinogen Medical Limited | -12.83 Million AUD | -250.004% |
| Immuron Limited | -5.8 Million AUD | -674.627% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -692.372% |